The clinical trial sponsored by Massachusetts Eye and Ear Infirmary aims to evaluate the efficacy of 5-fluorouracil (5-FU) in reducing complications associated with periocular full thickness skin grafts. Given the limited options for managing scarring and graft shrinkage in oculofacial surgery, a successful outcome could position 5-FU as a novel adjunct therapy in this niche market. The potential to enhance patient satisfaction and reduce the need for corrective surgeries could lead to significant adoption among ophthalmic surgeons. However, challenges in patient recruitment may hinder the trial's robustness and subsequent market entry. Competitive analysis reveals that while corticosteroids are currently the standard treatment, 5-FU could offer a safer alternative with fewer side effects, particularly in sensitive periocular applications.